We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Microsaic Systems Plc | LSE:MSYS | London | Ordinary Share | GB00BMWC8365 | ORD GBP0.00001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.825 | 0.80 | 0.85 | 0.825 | 0.825 | 0.83 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Components, Nec | 492k | -2.6M | -0.0145 | -0.57 | 1.48M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/10/2021 12:13 | Oh hello!https://www.th | tradingit | |
05/10/2021 08:34 | Share price as impressed as ever ! | daveboy19 | |
27/9/2021 14:59 | Outlook -- The Board anticipates the sales momentum of H1 to continue in H2 based on its sales pipeline. Potential collaborations and trials with DeepVerge may lead to significant opportunities in environmental water detection -- During the second half of 2021 the Board expects full agreements to be signed with its Chinese Partners for the assembly, distribution and servicing of its product in China, ahead of achieving a medical device licence in China for therapeutic drug monitoring in 2022 -- Furthermore, in H2 , Microsaic intends to appoint a contract research organisation ("CRO") to undertake cell line work in bioreactors before placing its bioprocessing technology and services with end-user biopharma for beta trials, ahead of expected commercialisation in 2022 -- The Company expects to launch a new detection platform in H2, targeting a wider range of chemical contaminants in water. This will further augment the combined chemical/pathogen detection capabilities between DeepVerge and Microsaic | ragnarr | |
27/9/2021 13:14 | Thanks for the extra info ragnarr. Over 4m cash in bank and very confident outlook, 12.5% drop seems about par these days. Hilarious. | paleje | |
27/9/2021 13:13 | Forgot to mention Hanson Fine Chemicals Hanson Fine Chemicals is associated with Hanson China Partners and a member of the UK based HANSON group of companies. Hanson Fine Chemicals, is a sister company to Sinojie Hanson, based in Hong Kong and Shanghai. Working together with Sinojie Hanson, Hanson Fine Chemical supplies western pharmaceutical and agro-chemical companies advanced intermediates and other custom manufactured compounds that are made in China. Through our sister company Sinojie Hanson, we work with and represent a variety of world-class chemical manufacturers in China. | ragnarr | |
27/9/2021 13:07 | Just been looking into the recent service agreement with Jiangsu Henzhihe Technologies Co. Ltd as they are a new entity. FYI Abbin Huang(MD)is also one of the founding partners and current directors of Sinojie Ltd SINOJIE LIMITED was originally formed in 2005 with the aim of providing a first class fine chemical sourcing, development and supply organization in the People's Republic of China targeted at Western world markets and particularly Europe The Hanson group took a controlling interest in 2012.(re-named to Sinojie Hanson) The Hanson group also includes Hanson Logistics, Hanson Boxes Ltd, Hanson Family Holdings, Hanson Capital, Hanson Wealth Management and Hanson Strand. Chaired by The Hon Robert Hanson who is also on the Board of Oberon Investment Group plc (AQSE OBE) | ragnarr | |
27/9/2021 08:56 | Always the same theses days when results come out - unless there is something unexpectedly spectacular the traders push the price back down . These are a very solid set of results clearly showing the recovery is underway and growth is underway. Personally very happy with everything and as a LTH adding whilst price is low. | ragnarr | |
27/9/2021 08:43 | Yes, Glen is thrilled, but sadly the market isn't ! | daveboy19 | |
27/9/2021 08:42 | Going going going gone!! | daar | |
27/9/2021 06:05 | Results out | janhar | |
24/9/2021 13:49 | You might need to explain that to him in more detail I think. Although to be fair there is an awful of cheap stock on this and it has been sold down daily for months and months by profit taking placees. | mrscocker | |
24/9/2021 13:40 | Shares in issue makes no difference. It's the cap that matters. | david gruen | |
24/9/2021 06:12 | Microsaic Systems plc 24 September 2021 24 September 2021 Microsaic Systems plc ("Microsaic" or the "Company") Microsaic sign manufacturing, supply, and service agreement to support China operations Production assembly to commence this year and on track for China medical device licence in 2022 Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments and solutions, is pleased to announce it has signed an agreement with Jiangsu Henzhihe Technologies Co. Ltd. ("HZH"), to support the Company's relationship with the Chinese distributor (the "Distributor"), with whom the Company announced a signed Heads of Terms for its micro-engineered MS technology (per the RNS dated 4 May 2021). Under the agreement ("Agreement"), HZH will provide integration and service support for Microsaic's operations in China. HZH will act as the manufacturer, integrator, and service centre in support of distribution and prospective OEM partnerships in China. HZH is a recently incorporated entity whose directors have a long history of working with MS in China and manufacturing other analytical devices, and in active pharmaceutical ingredients ("API"). Their relationships include large analytical instrumentation and pharmaceutical companies. HZH and Microsaic will collaborate with distribution partners to access and service other substantial growth opportunities in the Chinese market. Production in China of the MS hospital diagnostic monitoring equipment is expected to commence before the end of this year to support the Chinese Distributor through local production and service support, which are pre-requisites to securing a medical license . The Agreement establishes a local presence for Microsaic, accelerating the Company's growth opportunity in China. With an addressable market of 33,000 hospitals having 7.9 million beds(1) , having the ability to scale local production for MS therapeutic drug monitoring ("TDM") and maintain supply and service capability is essential. Multiple revenue streams are expected in due course, consisting of the sale of MS TDM units, franchise services and sales of reagents, in-line with Microsaic's business strategy. Once the medical license in China has been secured in 2022, HZH and the Company estimate a target rising to 100 units per annum for each therapeutic drug monitoring sector over the next two to three years, and there several sectors in this market and in other analytical sectors. HZH has confirmed it can meet the prospective demand requirements of Microsaic for China and the rest of the world. Glenn Tracey, CEO of Microsaic Systems plc, commented: "With the Company on track to secure a China medical device licence in 2022, developing the capability with local partners for mass production of Microsaic equipment in China represents a significant opportunity to reduce costs and increase available margins for these devices. This demonstrates our commitment to position our point-of-need technology in a broad range of key verticals within the human health diagnostics sector. "With a focus on commercialisation of sample-to-result platforms, and equipment with network management software capability (and later artificial intelligence ("AI") software, we look forward to providing further updates on production and distribution to the market as they arise ." Abbin Huang, MD of HZH, commented: "The Microsaic miniaturised mass spectrometers are unique and of great interest for a range of markets in China. We particularly see great potential in clinical and bioprocessing applications where real-time, point - of - need data is extremely valuable. We look forward to a long-term and close collaboration with Microsaic to serve the needs of the Chinese market ." (1) China Hospital Industry Report, 2019-2025 | david gruen | |
01/9/2021 22:58 | Sorry who you talking about | hodhasharen | |
01/9/2021 07:36 | Yep, seen similar on another board, where a guy called some dodgy traders out for underhand tactics, and now they follow him around incessantly trying to blacken his name, when all the time it is they who are up to no good. They also copy usernames and band together like hyenas. Disgusting. | daveboy19 | |
01/9/2021 07:29 | Please don't mistake hodhasharen for the real Hoddles (the one with the long standing paid account who created this thread). hodhasharen is Peaky Trader. He claimed for months to be topping up on SYME. Claimed to have 122 Million Shares. He posted a screenshot. Guess what! He had 1.22 Million. We laughed at him and he's taking some kind of revenge. | david gruen | |
01/9/2021 07:24 | Give me strength. | daveboy19 | |
01/9/2021 06:28 | Heading south very fast. 0.0001p today.In TW we trust and prosper. | hodhasharen | |
31/8/2021 08:46 | Another Zak Mir "tip" and guess what, the share price drops.Happens every time he says it will rise, it falls.Just saying. | mrscocker |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions